MRI Scan and Intra-labyrinthine Schwannoma

INTEREST OF INTRAVENOUS INJECTION OF GADOLINIUM IN EXPLORATION INTRA-LABYRINTHINE SCHWANNOMA IN MRI 3 TESLAS

Evaluate the interest of gadolinium for the positive and topographic diagnosis of intra-labyrinthine schwannoma, comparing T1 sequence acquired after gadolinium injection to a sequence of fast imaging type employing steady state acquisition (FIESTA-C)

Study Overview

• Status: Unknown
• Conditions: Schwannoma
• Intervention / Treatment: Other: No intervention in this restrospective study

• Study Type: Observational
• Enrollment (Anticipated): 30

Contacts and Locations

Study Locations

• France
  • Strasbourg, France, 67098
    • Recruiting
    • Service Imagerie 1

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patient having intra-labyrinthine schwannoma

Description

Inclusion Criteria:

• Age 18-80 years
• Have intra-labyrinthine schwannoma
• Have benefited from an MRI with gadolinium injection on the MRI 3T with interpretable sequences of good quality
• Subject giving their consent for their participation
• Subjects who benefited, between 2009 and 2016, from an MRI of the external auditory canals, with gadolinous product injection and on the 3 Tesla MRI, in which a diagnosis of intra labyrinthine schwannoma was made

Exclusion Criteria:

- Refusal to participate in the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA alone	1 hour after the realization of the MRI

Collaborators and Investigators

• Sponsor: University Hospital, Strasbourg, France

Study record dates

Study Major Dates

• Study Start (ACTUAL): February 2, 2018
• Primary Completion (ANTICIPATED): February 1, 2019
• Study Completion (ANTICIPATED): February 1, 2019

Study Registration Dates

• First Submitted: February 26, 2018
• First Submitted That Met QC Criteria: June 25, 2018
• First Posted (ACTUAL): July 9, 2018

Study Record Updates

• Last Update Posted (ACTUAL): July 13, 2018
• Last Update Submitted That Met QC Criteria: July 11, 2018
• Last Verified: February 1, 2018

More Information

Terms related to this study

• Keywords: magnetic resonance imaging (MRI); gadolinium; schwannoma; intra labyrinthine schwannoma; T2 weighted gradient echo
• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Neuroendocrine Tumors; Nerve Sheath Neoplasms; Neuroma; Neurilemmoma
• Other Study ID Numbers: 6809

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No